|
Name |
14-Methoxytajixanthone
|
| Molecular Formula | C26H28O7 | |
| IUPAC Name* |
(1R,2S)-8-[(S)-[(2S)-3,3-dimethyloxiran-2-yl]-methoxymethyl]-1,11-dihydroxy-5-methyl-2-prop-1-en-2-yl-2,3-dihydro-1H-pyrano[3,2-a]xanthen-12-one
|
|
| SMILES |
CC1=CC2=C(C3=C1OC[C@@H]([C@H]3O)C(=C)C)C(=O)C4=C(C=CC(=C4O2)[C@@H]([C@H]5C(O5)(C)C)OC)O
|
|
| InChI |
InChI=1S/C26H28O7/c1-11(2)14-10-31-22-12(3)9-16-18(19(22)20(14)28)21(29)17-15(27)8-7-13(23(17)32-16)24(30-6)25-26(4,5)33-25/h7-9,14,20,24-25,27-28H,1,10H2,2-6H3/t14-,20-,24+,25+/m1/s1
|
|
| InChIKey |
GHOFXWXPHPERFR-HYWGBUEBSA-N
|
|
| Synonyms |
14-methoxytajixanthone; CHEMBL515370; BDBM50266274; (1R,2S)-8-[(S)-[(2S)-3,3-dimethyloxiran-2-yl]-methoxymethyl]-1,11-dihydroxy-5-methyl-2-prop-1-en-2-yl-2,3-dihydro-1H-pyrano[3,2-a]xanthen-12-one
|
|
| CAS | NA | |
| PubChem CID | 25211345 | |
| ChEMBL ID | CHEMBL515370 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 452.5 | ALogp: | 3.9 |
| HBD: | 2 | HBA: | 7 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 97.8 | Aromatic Rings: | 5 |
| Heavy Atoms: | 33 | QED Weighted: | 0.328 |
| Caco-2 Permeability: | -4.843 | MDCK Permeability: | 0.00001290 |
| Pgp-inhibitor: | 0.923 | Pgp-substrate: | 0.594 |
| Human Intestinal Absorption (HIA): | 0.102 | 20% Bioavailability (F20%): | 0.002 |
| 30% Bioavailability (F30%): | 0.011 |
| Blood-Brain-Barrier Penetration (BBB): | 0.025 | Plasma Protein Binding (PPB): | 85.02% |
| Volume Distribution (VD): | 0.993 | Fu: | 10.66% |
| CYP1A2-inhibitor: | 0.101 | CYP1A2-substrate: | 0.957 |
| CYP2C19-inhibitor: | 0.048 | CYP2C19-substrate: | 0.565 |
| CYP2C9-inhibitor: | 0.49 | CYP2C9-substrate: | 0.366 |
| CYP2D6-inhibitor: | 0.105 | CYP2D6-substrate: | 0.26 |
| CYP3A4-inhibitor: | 0.2 | CYP3A4-substrate: | 0.302 |
| Clearance (CL): | 2.041 | Half-life (T1/2): | 0.044 |
| hERG Blockers: | 0.01 | Human Hepatotoxicity (H-HT): | 0.711 |
| Drug-inuced Liver Injury (DILI): | 0.951 | AMES Toxicity: | 0.684 |
| Rat Oral Acute Toxicity: | 0.663 | Maximum Recommended Daily Dose: | 0.679 |
| Skin Sensitization: | 0.491 | Carcinogencity: | 0.86 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.199 |
| Respiratory Toxicity: | 0.411 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002697 | ![]() |
0.664 | D0Q0PR | ![]() |
0.284 | ||
| ENC002341 | ![]() |
0.644 | D0F7CS | ![]() |
0.276 | ||
| ENC002623 | ![]() |
0.632 | D06GCK | ![]() |
0.254 | ||
| ENC002651 | ![]() |
0.630 | D0K8KX | ![]() |
0.242 | ||
| ENC004314 | ![]() |
0.581 | D04TDQ | ![]() |
0.234 | ||
| ENC002916 | ![]() |
0.555 | D0O6KE | ![]() |
0.231 | ||
| ENC006093 | ![]() |
0.555 | D0H0SJ | ![]() |
0.231 | ||
| ENC004145 | ![]() |
0.547 | D0R9WP | ![]() |
0.227 | ||
| ENC005491 | ![]() |
0.496 | D0FX2Q | ![]() |
0.227 | ||
| ENC004538 | ![]() |
0.440 | D0O1UZ | ![]() |
0.226 | ||